Assessment of Treatment With Sorafenib Plus Doxorubicin vs Sorafenib Alone in Patients With Advanced Hepatocellular Carcinoma Abou-Alfa, Ghassan K. , Shi, Qian , Knox, Jennifer J. ... - - JAMA Oncol - 2019 Manuscript - Primary - Primary - GI - CALGB-80802
Platelet count at baseline (Plt) and outcomes in patients (pts) with advanced hepatocellular carcinoma (HCC) treated with sorafenib (S) in CALGB 80802 (Alliance) (C8) Abou-Alfa, Ghassan K. , Shi, Qian , Knox, Jennifer J. ... - ASCO - J Clin Oncol - 2018 Abstract - Secondary-not-in-original - Primary - GI - CALGB-80802
Feasibility of Implementing the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events in a Multicenter Trial: NCCTG N1048 Basch, Ethan , Dueck, Amylou C. , Rogak, Lauren J. ... - - J. Clin. Oncol - 2018 Manuscript - Secondary-not-in-original - Primary - Health Outcome - N1048
Alliance A071101: A Phase II Randomized Trial Comparing the Efficacy of Heat Shock Protein-Peptide Complex-96 (HSPPC-96) Vaccine Given with Bevacizumab versus Bevacizumab Alone in the Treatment of Surgically Resectable Recurrent Glioblastoma Bloch, Orin , Shi, Qian , Anderson, S. Keith , Knopp, Michael ... - SNO - Neuro-Oncology - 2017 Abstract - Primary - Primary - Neuro-Onc - A071101
Development of Clinical Precision Medicine Approaches in Meningiomas: Alliance A071401. Brastianos, Priscilla , Shi, Qian , Santagata, Sandro ... - SNOM - - 2016 Abstract - No-Endpoint - Trial-Description-Only - Neuro-Onc - A071401
The Predictive and Prognostic Value of Sex in Early-Stage Colon Cancer: A Pooled Analysis of 33,345 Patients from the ACCENT Database Cheung, Winson Y. , Shi, Qian , O’Connell, Michael , Cassidy, James ... - - Clin Colorectal Cancer - 2013 Manuscript - Secondary - Primary - GI - N0441
A cluster-randomized study of clinician-patient shared vs standard reporting of symptomatic adverse events using PRO-CTCAE nested in a multicenter trial of multimodal therapy for rectal cancer (Alliance N1048 PROSPECT) Dueck, Amylou C. , Mitchell, S.A. , Rogak, Lauren I. , Ginos, Brenda ... - ISOQOL - Qual Life Res - 2015 Abstract - Secondary - Primary - GI - N1048
Tumor Response and Progression-Free Survival as Potential Surrogate Endpoints for Overall Survival in Extensive-Stage Small Cell Lung Cancer (ES-SCLC): Findings Based on North Central Cancer Treatment Group (NCCTG) Trials Foster, Nathan R. , Qi, Yingwei , Shi, Qian , Krook, James E. ... - - Cancer - 2011 Manuscript - Primary - Primary - Respiratory - N0424
Treatment of Colorectal Peritoneal Carcinomatosis With Systemic Chemotherapy: A Pooled Analysis of North Central Cancer Treatment Group Phase III Trials N9741 and N9841 Franko, Jan , Shi, Qian , Goldman, Charles D. , Pockaj, Barbara A. ... - - J Clin Oncol - 2012 Manuscript - Secondary-not-in-original - Comprehensive - GI - N9841 , N9741
Organ preservation for clinical t2n0 distal rectal cancer using neoadjuvant chemoradiotherapy and local excision: results of a multicenter phase 2 study Garcia-Aguilar, Julio , Renfro, Lindsay A. , Chow, Oliver S. ... - - Lancet Oncol. - 2015 Manuscript - Secondary - Primary - GI - ACOSOG-Z6041
A Phase II Trial of Neoadjuvant Chemoradiation and Local Excision for T2N0 Rectal Cancer: Preliminary Results of the ACOSOG Z6041 Trial Garcia-Aguilar, Julio , Shi, Qian , Thomas, Charles R. , Chan, Emily ... - - Ann. Surg. Oncol. - 2012 Manuscript - Primary - Preliminary - GI - ACOSOG-Z6041
Variability of Pelvic MRI Performance in a Prospective Multicenter Rectal Cancer Trial NCCTG N1048 (Alliance) Gollub, Marc J. , Shi, Qian , Nougaret, Stephanie ... - ASCO - J Clin Oncol - 2018 Abstract - Secondary-not-in-original - Primary - GI - N1048
Prospective pooled analysis of six phase III trials investigating duration of adjuvant (adjuv) oxaliplatin-based therapy (3 vs 6 months) for patients (pts) with stage III colon cancer (CC): The IDEA (International Duration Evaluation of Adjuvant chemotherapy) collaboration Grothey, Axel , Sobrero, Alberto F. , Meyerhardt, Jeffrey A. ... - ESMO - Annals of Oncology - 2017 Abstract - Secondary-not-in-original - Comprehensive - GI - CALGB-80702
Benefits and Adverse Events in Younger Versus Older Patients Receiving Adjuvant Chemotherapy for Colon Cancer: Findings From the Adjuvant Colon Cancer Endpoints Data Set Hubbard, Joleen , Thomas, David M. , Yothers, Greg , Green, Erin ... - - J. Clin. Oncol - 2012 Manuscript - Secondary - Comprehensive - GI - ACCENT , CALGB-89803
Alliance for clinical trials in oncology (ALLIANCE) trial A021501: preoperative extended chemotherapy vs. chemotherapy plus hypofractionated radiation therapy for borderline resectable adenocarcinoma of the head of the pancreas Katz, Matthew H. G. , Ou, Fang-Shu , Herman, Joseph M. ... - - BMC Cancer - 2017 Manuscript - No-Endpoint - Trial-Description-Only - GI - A021501
Preoperative Modified FOLFIRINOX Treatment Followed by Capecitabine-Based Chemoradiation for Borderline Resectable Pancreatic Cancer Katz, Matthew H. G. , Shi, Qian , Ahmad, Syed A. , Herman, Joseph M. ... - - JAMA Surg - 2016 Manuscript - Primary - Primary - GI - A021101
Preoperative modified FOLFIRINOX (mFOLFIRINOX) followed by chemoradiation (CRT) for borderline resectable (BLR) pancreatic cancer (PDAC): Initial results from Alliance Trial A021101. Katz, Matthew H.G. , Shi, Qian , Ahmad, Syed , Herman, Joseph ... - ASCO - J. Clin. Oncol. - 2015 Abstract - Primary - Primary - GI - A021101
Borderline resectable pancreatic cancer: Need for Standardization and Methods for Optimal Clinical Trial Design Katz, Matthew HG , Marsh, Robert , Herman, Joseph M. , Shi, Qian ... - - Ann. Surg. Oncol. - 2013 Manuscript - No-Endpoint - Comprehensive - GI - A021101
HapB3 and the deep intronic variant c.1129-5923 C>G of the dihydropyrimidine dehydrogenase gene (DPYD) as predictors of toxicity in Stage III colon cancer (CC) patients (pts) (NCCTG N0147) (Alliance) Lee, Adam M. , Shi, Qian , Alberts, Steven R. , Sargent, Daniel J. ... - ASCO GI - J. Clin. Oncol. - 2015 Abstract - Secondary - Primary - Correl Sci NOS - N0147
Association between DPYD c.1129-5923 C>G/hapB3 and severe toxicity to 5-fluorouracil-based chemotherapy in stage III colon cancer patients: NCCTG N0147 (Alliance) Lee, Adam M. , Shi, Qian , Alberts, Steven R. , Sargent, Daniel J. ... - - Pharmacogenet. Genomics - 2016 Manuscript - Secondary - Primary - Correl Sci NOS - N0147
DPYD Variants as Predictors of 5-fluorouracil Toxicity in Adjuvant Colon Cancer Treatment (NCCTG N0147) Lee, Adam M. , Shi, Qian , Pavey, Emily , Alberts, Steven R. ... - - J. Natl. Cancer Inst - 2014 Manuscript - Secondary-not-in-original - Primary - Correl Sci NOS - NCCTG-N0147
Association of micropapillary architecture and high tumor budding with prognosis in patients with stage III colon cancer from a FOLFOX-based adjuvant chemotherapy trial: NCCTG N0147 (Alliance) Lee, Hee Eun , Shi, Qian , Foster, Nate , Chan, Emily , Gill, Sharlene ... - USCAP - Mod Pathol - 2017 Abstract - Secondary-not-in-original - Primary - Correl Sci NOS - NCCTG-N0147
Genetic correlates of therapeutic toxicities of stage III colon cancer (CC) patients treated with adjuvant FOLFOX+/-cetuximab (Alliance NCCTG N0147) Newcomb, Polly A. , Sun, Wei , Hua, Xinwei , Banbury, Barbara ... - ASCO - J. Clin. Oncol. - 2017 Abstract - Secondary - Primary - PPP - NCCTG-N0147
Milestone prediction for time-to-event endpoint monitoring in clinical trials Ou, Fang-Shu , Heller, Martin ... - - Pharm Stat - 2019 Manuscript - No-Endpoint - Other - GI - A151730
Genetic Variant Associated with Survival of Patients with Stage II-III Colon Cancer Penney, Kathryn L. , Banbury, Barbara L. , Bien, Stephanie ... - - Clin. Gastroenterol. Hepatol. - 2019 Manuscript - Secondary-not-in-original - Primary - Correl Sci NOS - N0147
Genome-wide association with survival in stage II-III colon cancer (CC) clinical trials (NCCTG N0147, Alliance for Clinical Trials in Oncology; NSABP C-08, NRG Oncology) Penney, Kathryn , Banbury, Barbara L. , Shi, Qian ... - ASCO - J Clin Oncol - 2018 Abstract - Secondary-not-in-original - Primary - PPP - N0147
Pre-diagnostic physical activity and outcomes in patients with stage III colon cancer: A correlative analysis of phase III trial NCCTG N0147 (Alliance) Phipps, Amanda I. , Shi, Qian , Chan, Emily , Gill, Sharlene ... - ASPO - - 2017 Abstract - Secondary - Primary - GI - NCCTG-N0147
Alcohol consumption and colon cancer prognosis among participants in North Central Cancer Treatment Group phase III trial N0147 Phipps, Amanda I. , Shi, Qian , Limburg, Paul J. , Nelson, Garth D. ... - - Int. J. Cancer - 2016 Manuscript - Secondary - Primary - GI - N0147
Alcohol consumption and prognosis in patients with stage III colon cancer: a correlative analysis of NCCTG phase III trial N0147 Phipps, Amanda I. , Shi, Qian , Limburg, Paul J. , Nelson, Garth D. ... - ASCO - J. Clin. Oncol. - 2015 Abstract - Secondary - Primary - GI - N0147
Physical activity and outcomes in patients with stage III colon cancer: A correlative analysis of phase III trial NCCTG N0147 (Alliance) Phipps, Amanda I. , Shi, Qian , Zemla, Tyler J. , Dotan, Efrat ... - - Cancer Epidemiol. Biomarkers Prev. - 2018 Manuscript - Secondary-not-in-original - Primary - GI - NCCTG-N0147
Challenges and Solutions in the Design and Execution of the PROSPECT Phase II/III Neoadjuvant Rectal Cancer Trial (NCCTG N1048/Alliance) Schrag, Deborah , Weiser, Martin , Saltz, Leonard , Mamon, Harvey ... - - Clin Trials - 2019 Manuscript - Secondary-not-in-original - Primary - GI - N1048
Association study of the let-7 microrna-binding site polymorphism in 3-untranslated region (UTR) of the KRAS gene in stage III colon cancers from adjuvant trial NCCTG N0147 Sha, Dan , Lee, Adam , Shi, Qian , Alberts, Steven R. ... - ASCO - J. Clin. Oncol. - 2012 Abstract - Secondary-not-in-original - Primary - Correl Sci NOS - NCCTG-N0147
Association study of the let-7 miRNA-complementary site variant in the 3’ untranslated region of the KRAS gene in stage III colon cancer (NCCTG N0147 clinical trial) Sha, Dan , Lee, Adam , Shi, Qian , Alberts, Steven R. ... - - Clin. Cancer Res. - 2014 Manuscript - Secondary-not-in-original - Primary - Correl Sci NOS - N0147
Comparison of Outcomes After Fluorouracil-Based Adjuvant Therapy for Stages II and III Colon Cancer Between 1978 to 1995 and 1996 to 2007: Evidence of Stage Migration From the ACCENT Database Shi, Qian , Andre, Thierry , Grothey, Axel , Yothers, Greg ... - - J. Clin. Oncol. - 2013 Manuscript - Secondary-not-in-original - Meta-Analysis - GI - CALGB-89803 , NCCTG-784852 , NCCTG-874651 , NCCTG-894651 , NCCTG-914653
Prospective pooled analysis of six phase III trials investigating duration of adjuvant oxaliplatin-based therapy (3 versus 6 months) for patients with stage III colon cancer: The IDEA (International Duration Evaluation of Adjuvant chemotherapy) collaboration (Alliance) Shi, Qian , Sobrero, Alberto , Shields, Anthony , Yoshino, Takayuki ... - ASCO - J. Clin. Oncol. - 2017 Abstract - Secondary-not-in-original - Primary - GI - CALGB-80702
Cancer registries: a novel alternative to long-term clinical trial follow-up based on results of a comparative study Shi, Qian , You, Y Nancy , Nelson, Heidi , Allen, Mark S ... - - Clin Trials - 2010 Manuscript - Secondary-not-in-original - Primary - Respiratory - ACOSOG-Z0030
Effect of age, gender, and performance status (PS) on the duration results of adjuvant chemotherapy for stage III colon cancer: the IDEA collaboration Shields, Anthony F. , Ou, Fang-Shu , Paul, James ... - ASCO - J Clin Oncol - 2018 Abstract - Secondary-not-in-original - Primary - GI - CALGB-80702
Relationship Between Metformin Use and Recurrence and Survival in Patients With Resected Stage III Colon Cancer Receiving Adjuvant Chemotherapy: Results From North Central Cancer Treatment Group N0147 (Alliance) Singh, Preet Paul , Shi, Qian , Foster, Nathan R. , Grothey, Axel ... - - Oncologist - 2016 Manuscript - Secondary-not-in-original - Primary - GI - NCCTG-N0147
Relationship between Metformin use and Recurrence and Survival in Patients (pts) with Resected Stage III Colon Cancer (CC) Receiving Adjuvant Chemotherapy: Results from NCCTG N0147 (Alliance) Singh, Preet Paul , Shi, Qian , Foster, Nathan , Grothey, Axel ... - ASCO - J. Clin. Oncol. - 2015 Abstract - Secondary-not-in-original - Primary - GI - N0147
Association of DNA Mismatch Repair and Mutations in BRAF and KRAS with Survival after Recurrence in Stage III Colon Cancers from Phase III Adjuvant Chemotherapy Trials Sinicrope, Frank A. , Shi, Qian , Allegra, Carmen J. ... - - JAMA Oncol - 2017 Manuscript - Secondary-not-in-original - Comprehensive - Correl Sci NOS - NCCTG-N0147
Molecular markers and survival after recurrence in stage III colon cancers from NCCTG N0147 and NSABP C-08 adjuvant chemotherapy trials Sinicrope, Frank A. , Shi, Qian , Allegra, Carmen Joseph ... - ASCO - J. Clin. Oncol. - 2016 Abstract - Secondary-not-in-original - Primary - Correl Sci NOS - N0147
Immunoscore provides prognostic information in low (T1-3N1) and high risk (T4 or N2) subsets of stage III colon carcinoma patients treated with adjuvant FOLFOX in a phase III trial (NCCTG N0147; Alliance) Sinicrope, Frank A. , Shi, Qian , Hermitte, Fabienne ... - ASCO GI - J Clin Oncol - 2018 Abstract - Secondary-not-in-original - Primary - Correl Sci NOS - N0147
Prognostic utility of immune markers and validation of Immunoscore in stage III colon carcinoma patients treated with adjuvant FOLFOX in a phase III trial (NCCTG N0147; Alliance) Sinicrope, Frank A. , Shi, Qian , Hermitte, Fabienne ... - ESMO GI - Annals of Oncology - 2017 Abstract - Secondary-not-in-original - Primary - Correl Sci NOS - N0147
Association of an immunoscore with survival of stage III colon cancer (CC) patients treated with adjuvant FOLFOX (Alliance N0147) Sinicrope, Frank A. , Shi, Qian , Hermitte, Fabienne , Heying, Erica ... - ASCO - J. Clin. Oncol. - 2017 Abstract - Secondary-not-in-original - Primary - Correl Sci NOS - NCCTG-N0147
Validation of tumor infiltrating lymphocytes (TIL) and tumor budding as predictors of prognosis in patients with stage III colon cancers treated in a FOLFOX-based adjuvant therapy trial: NCCTG N0147 (Alliance) Sinicrope, Frank A. , Shi, Qian , Lee, Hee Eun , Foster, Nathan R. ... - ASCO - J Clin Oncol - 2018 Abstract - Secondary-not-in-original - Primary - Correl Sci NOS - N0147
Analysis of serum vitamin D levels and prognosis in stage III colon carcinoma patients treated with adjuvant FOLFOX+/- cetuximab chemotherapy (NCCTG N0147) (Alliance) Sinicrope, Frank A. , Shi, Qian , Smyrk, Thomas C. ... - ASCO - J. Clin. Oncol. - 2017 Abstract - Secondary - Primary - Correl Sci NOS - NCCTG-N0147
Molecular Markers Identify Subtypes of Stage III Colon Cancer Associated with Patient Outcomes Sinicrope, Frank A. , Shi, Qian , Smyrk, Thomas C. ... - - Gastroenterology - 2015 Manuscript - Secondary - Primary - Correl Sci NOS - N0147
Molecular subtyping of colon cancers and distinct prognostic groups [NCCTG N0147 (Alliance)]. Sinicrope, Frank A. , Shi, Qian , Thibodeau, Stephen N. ... - ASCO - J. Clin. Oncol. - 2014 Abstract - Secondary - Primary - Correl Sci NOS - N0147
Association Of Tumor Infiltrating Lymphocytes (Tils) With Molecular Subtype And Prognosis In Stage III Colon Cancers From A FOLFOX-Based Adjuvant Chemotherapy Trial: NCCTG N0147 (Alliance) Sinicrope, Frank A. , Smyrk, Thomas C. , Foster, Nathan R. ... - ASCO - J. Clin. Oncol. - 2016 Abstract - Secondary - Primary - Correl Sci NOS - NCCTG-N0147
Mutation-Specific Antibody Detects Mutant BRAFV600E Protein Expression in Human Colon Carcinomas Sinicrope, Frank A. , Smyrk, Thomas C. , Tougeron, David ... - - Cancer - 2013 Manuscript - Secondary - Primary - Correl Sci NOS - N0147
Contribution of Immunoscore and Molecular Features to Survival Prediction in Stage III Colon Cancer Sinicrope, Frank A , Shi, Qian , Hermitte, Fabienne , Zemla, Tyler J ... - - JNCI Cancer Spectr - 2020 Manuscript - Secondary-not-in-original - Primary - Correl Sci NOS - N0147
Marine omega-3 fatty acid intake and survival of stage III colon cancer according to tumor molecular markers in NCCTG Phase III trial N0147 (Alliance) Song, Mingyang , Ou, Fang-Shu , Zemla, Tyler J. , Hull, Mark A. ... - - Int. J. Cancer - 2019 Manuscript - Secondary-not-in-original - Primary - GI - N0147
Postdiagnosis marine omega-3 fatty acid intake and survival of stage III colon cancer in North Central Cancer Treatment Group phase III trial N0147 (Alliance) Song, Mingyang , Ou, Fang-Shu , Zemla, Tyler J. , Shi, Qian ... - DDW - Gastroenterology - 2018 Abstract - Secondary-not-in-original - Primary - GI - NCCTG-N0147
Prognostic Value of BRAF and KRAS Mutations in MSI and MSS Stage III Colon Cancer Taieb, Julien , Le Malicot, Karine , Shi, Qian ... - - J. Natl. Cancer Inst - 2016 Manuscript - Secondary-not-in-original - Primary - Correl Sci NOS - N0147
Prognostic value of BRAF V600E and KRAS exon 2 mutations in microsatellite stable (MSS), stage III colon cancers (CC) from patients (pts) treated with adjuvant FOLFOX+/- cetuximab: A pooled analysis of 3934 pts from the PETACC8 and N0147 trials Taieb, Julien , Malicot, Karine Le ... - ASCO - J Clin Oncol - 2015 Abstract - Secondary-not-in-original - Comprehensive - Correl Sci NOS - N0147
Perioperative gemcitabine + erlotinib plus pancreaticoduodenectomy for resectable pancreatic adenocarcinoma: ACOSOG Z5041 (Alliance) phase II trial Wei, Alice C. , Ou, Fang-Shu , Shi, Qian , Carrero, Xiomara ... - - Ann. Surg. Oncol. - 2019 Manuscript - Primary - Primary - GI - ACOSOG-Z5041
A phase II study of pre- and post-operative gemcitabine and erlotinib plus pancreaticoduodenectomy (PD) for patients with resectable pancreatic ductal adenocarcinoma (PDAC): ACOSOG/ Alliance Z5041 Trial Wei, Alice Chia-chi , Ou, Fang-Shu , Shi, Qian ... - ASCO - J. Clin. Oncol - 2018 Abstract - Primary - Primary - GI - ACOSOG-Z5041
Influence of molecular alterations on site-specific (ss) time to recurrence (TTR) following adjuvant therapy in resected colon cancer (CC) Wilcox, Ryan E. , Shi, Qian , Sinicrope, Frank A. ... - ASCO - J. Clin. Oncol. - 2015 Abstract - Secondary - Primary - Correl Sci NOS - N0147
Deletions in HSP110 T17 and Patient Prognosis in Stage III Microsatellite Instable (MSI) Colon Cancers: Findings from CALGB 89803 and NCCTG N0147. Wu, Christina , Shi, Qian , Tomsic, Jerneja , Meyers, Jeffrey ... - ASCO - J. Clin. Oncol. - 2016 Abstract - Secondary-not-in-original - Primary - Correl Sci NOS - CALGB-89803 , NCCTG-N0147
Racial differences in KRAS/BRAF mutation rates and survival in colon cancer (NCCTG N0147 [Alliance]). Yoon, Harry H. , Shi, Qian , Alberts, Steven R. ... - ASCO - J. Clin. Oncol. - 2014 Abstract - Secondary-not-in-original - Primary - GI - N0147
Racial Differences in BRAF/KRAS Mutation Rates and Survival in Stage III Colon Cancer Patients Yoon, Harry H. , Shi, Qian , Alberts, Steven R. ... - - J. Natl. Cancer Inst - 2015 Manuscript - Secondary-not-in-original - Primary - GI - N0147
Inter-tumoral heterogeneity of CD3+ and CD8+ T-cell densities in the microenvironment of DNA mismatch repair-deficient colon cancers: implications for prognosis Yoon, Harry H. , Shi, Qian , Heying, Erica N. , Muranyi, Andrea ... - - Clin. Cancer Res. - 2019 Manuscript - Secondary-not-in-original - Primary - Correl Sci NOS - N0147
CD3+ and CD8+ tumor-infiltrating lymphocyte (TIL) densities prognostically stratify DNA mismatch repair-deficient (dMMR) colon cancer patients (pts): NCCTG N0147 (Alliance) Yoon, Harry H. , Shi, Qian , Heying, Erica N. , Muranyi, Andrea ... - ASCO - J Clin Oncol - 2018 Abstract - Secondary-not-in-original - Primary - Correl Sci NOS - N0147
KRAS codon 12 and 13 mutations in relation to disease-free survival in BRAF-wild type stage III colon cancers from an adjuvant chemotherapy trial (N0147 Alliance) Yoon, Harry H. , Tougeron, David , Shi, Qian , Alberts, Steven R. ... - - Clin. Cancer Res. - 2014 Manuscript - Secondary-not-in-original - Primary - Correl Sci NOS - N0147
Role of Deficient DNA Mismatch Repair Status in Patients With Stage III Colon Cancer Treated With FOLFOX Adjuvant Chemotherapy Zaanan, Aziz , Shi, Qian , Taieb, Julien , Alberts, Steven R. ... - - JAMA Oncol - 2018 Manuscript - Secondary-not-in-original - Primary - Correl Sci NOS - N0147
Clinical outcomes between familial and sporadic forms of colon cancer patients showing deficient DNA mismatch repair treated with adjuvant FOLFOX +/- cetuximab: A pooled analysis of the PETACC8 and NCCTG N0147 trials Zaanan, Aziz , Shi, Qian , Taieb, Julien , Alberts, Steven R. ... - - JCO Precision Oncology - 2020 Manuscript - Secondary-not-in-original - Primary - Correl Sci NOS - N0147
Analysis of DNA mismatch repair (MMR) and clinical outcome in stage III colon cancers from patients treated with adjuvant FOLFOX + cetuximab in the PETACC8 and N0147 adjuvant trials. Zaanan, Aziz , Shi, Qian , Taieb, Julien , Alberts, Steven R. ... - ASCO - J. Clin. Oncol. - 2015 Abstract - Secondary-not-in-original - Primary - Correl Sci NOS - N0147
Association Between Disease-Free Survival and Overall Survival When Survival Is Prolonged After Recurrence in Patients Receiving Cytotoxic Adjuvant Therapy for Colon Cancer: Simulations Based on the 20,800 Patient ACCENT Data Set de Gramont, Aimery , Hubbard, Joleen , Shi, Qian ... - - J Clin Oncol - 2010 Manuscript - Secondary - Primary - GI - N9741
